Preclinical and clinical pharmacology of antisense oligonucleotides

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 12, Issue 1, 1999, Pages 1-11

  Marcusson, E G ^a   Yacyshyn, B R ^b   Shanahan Jr , W R ^c   Dean, N M ^c  

^a Immusol Inc   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense oligonucleotides; CMV; Crohn's disease; Drug design; HIV

Indexed keywords

AFOVIRSEN; ALICAFORSEN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; FOMIVIRSEN; GENE EXPRESSION MODULATOR 132; GENE EXPRESSION MODULATOR 231; GENE EXPRESSION MODULATOR 92; INTERCELLULAR ADHESION MOLECULE 1; ISIS 13312; ISIS 2292; ISIS 2503; ISIS 3521; LR 3001; LR 3280; MESSENGER RNA; OBLIMERSEN; RIBONUCLEASE; TRECOVIRSEN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CLONING VECTOR; CROHN DISEASE; CYTOMEGALOVIRUS; DRUG DESIGN; DRUG EFFICACY; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MOLECULAR CLONING; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RETINITIS; REVIEW;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032707331     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:12:1:1     Document Type: Review

References (89)

1. Fujiwara, T., Grimm, E. A., and Roth, J. A., (1994) Gene therapeutics and gene therapy for cancer, Curr Opin Oncol, 6, 96.
2. Schreier, H., (1994) The new frontier: Gene and oligonucleotide therapy, Pharm Acta Helv, 68, 145.
3. Zameenik, P. C., and Stephenson, M. L., (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynbucleotJde, Proceedings of the National Academy of Sciences of the United States of America, 75, 289.
4. Thierry, A. R., and Dritschilo, A., (1992) Intracellular availability of unmodified, phosphorothioated and liposomally encupsulated oligodeoxynucleotides for antisense activity, Nucleic Acids Res, 20, 5691.
5. Campbell, J. M., Bacon, T. A., and Wickstrom, F., (1990) Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid, J Biochem Biophys Methods, 20, 259.
6. Akhtar, S., Kole, R., and Juliano, R. L., (1991) Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera, Life Sci, 49, 1793.
7. Kanaya, S., and Ikehara, M., (1995) Functions and structures of ribonuclease H enzymes, Subcell Biochem, 24, 377.
8. Lima, W. F., Brown-Driver, V., Fox, M., Hanecak, R., and Bruice, T. W., (1997) Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity, J Biol Chem. 272, 626.
9. Stein, C. A., and Cohen, J. S., (1988) Oligodeoxynucleotides as inhibitors of gene expression: A review, Cancer Res, 48, 2659.
10. Crooke, S. T., (1996) Proof of mechanism of antisense drugs, Antisense Nucleic Acid Drug Dev, 6, 145.
11. Stein, C. A., Matsukura, M., Subasinghe, C., Broder, S., and Cohen, J. S., (1989) Phosphorothioate oligodeoxynucleotides are potent sequence non- specific inhibilors of de novo infection by HIV, AIDS Res Hum Retroviruses, 5, 639.
12. Stein, C. A., and Cheng, Y. C., (1993) Antisense oligonucleotides tis therapeutic agents - Is the bullet really magical?, Science, 261, 1004.
13. Stein, C. A., (1992) Anti-sense oligodeoxynucleotides - Promises and pitfalls, Leukemia, 6, 967.
14. Matson, S., and Krieg, A. M., (1992) Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides, Antisense Res Dev, 2, 325.
15. Manev, H., Caredda, S., and Grayson, D. R., (1991) Nonselective inhibition by antisense oligonucleotides of cytosine arabinoside action, Neuroreport, 2, 589.
16. Ghosh. M. K., Ghosh, K., and Cohen, J. S., (1992) Translation inhibition by phosphorothioate oligodeoxynucleotides in cell-free systems, Antisense Res Dev. 2, 111.
17. Reed, J. C., Stein, C., Subasinghe, C., Haldar, S., Croce, C. M., Yum, S., and Cohen, J., (1990) Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides, Cancer Res, 50, 6565.
18. Dean, N. M., McKay, R., Condon, T. P., and Bennett, C. F., (1994) Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters, J Biol Chem, 269, 16416.
19. DiPaola, R. S., Kuczynski, W. I., Onodera, K., Ratajezak, M. Z., Hijiya, N., Moore, J., and Gewirtz, A. M., (1997) Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells, Cancer Gene Ther, 4, 176.
20. Roush, W., (1997) Antisense aims for a renaissance [news]. Science, 276, 1192.
21. Hall, T. J., and Brostoff. J., (1992) Specific inhibition of IgE antibody production by an antisense oligodeoxynucleotide oligomer (Oligoslick), Immunology, 77, 462.
22. Traub, O., Monia, B. P., Dean, N. M., and Berk, B. C., (1997) PKC-epsilon is required for mechano-sensitive activation off ERK1/2 in endothelial cells, J Biol Chem, 272, 31251.
23. Cioffi, C. L., Garay, M., Johnston, J. F., McGraw, K., Boggs, R. T., Hreniuk, D., and Monia, B. P., (1997) Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: Role of A- Raf and C-Raf in serum-induced proliferation, Mol Pharmacol, 51, 383.
24. Monia, B. P., Johnston, J. F., Ecker, D. J., Zounes, M. A., Lima, W. F., and Freier, S. M., (1992) Selective inhibition of mutant IIa-ras mRNA expression by antisense oligonucleotides, J Biol Chem, 267, 19954.
25. Bennett, C. F., Chiang, M.-Y., Chan, H., Shoemaker, J. E. E., and Mirabelli, C. K., (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides, Mol. Pharmacol., 41, 1023.
26. Giewirtz, A. M., Stein, C. A., and Glazer, P. M., (1996) Facilitating oligonucleotide delivery: Helping antisense deliver on its promise, Proc Natl Acad Sci U S A, 93, 3161.
27. Zelphati, O., and Szoka, F. C., Jr., (1996) Mechanism of oligonucleotide release from cationic liposomes, Proc Natl Acad Sci U S A, 93, 11493.
28. Zeiphati, O., and Szoka, F. C., Jr., (1996) Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids, Pharm Res, 13, 1367.
29. Marcusson, E. G., Bhat, B., Manoharan, M., Bennett, C. F., and Dean, N. M., (1998) Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus, Nucleic Acids Res, 26, 2016.
30. Miraglia, L., Geigler T., Bennett, C. F., and Dean, N. M., (1996) Inhibition of interleukin-1 lype 1 receptor expression in human cell-lines by an antisense phosphorothioate oligodeoxynucleotide, Int J Immunopharmacol 18, 227.
31. Stewart, A. J., Canitrot, Y., Baracchini, E., Dean, N. M., Deeley, R. G., and Cole, S. P., (1996) Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothiate oligonucleolides, Biochem Pharmacol, 51, 461.
32. Cossum, P. A., Sasmor, H., Dellinger, D., Truong, L., Cummins, L., Owens, S. R., Markham, P. M., Shea, J. P., and Crooke, S., (1993) Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats, J Pharmacol Exp Ther, 267, 1181.
33. Agrawat, S., Temsamani, J., Galbraith, W., and Tang, J., (1995) Pharmacokinetics of antisense oligonucleolides, Clin Pharmacokinet, 28, 7.
34. Dean, N. M., and McKay, R., (1994) Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides, Proc Natl Acad Sci U S A, 91, 11762.
35. Agrawal, S., Temsamani, J., and Tang, J. Y., (1991) Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice, Proc Natl Acad Sci U S A, 88, 7595.
36. Sands, H., Gorey-Feret, L. J., Cocuzza, A. J., Hobbs, F. W., Chidester, D., and Trainor, G. L., (1994) Biodistrihution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate, Mol Pharmacol, 45, 932.
37. Amaratunga, A., Morin, P. J., Kosik, K. S., and Fine, R. F., (1993) Inhibition of kinesin synthesis and rapid anterograde axonal transport in vivo by an antisense oligonucleotide, J Biol Chem, 268, 17, 427.
38. Higgins, K. A., Perez, J. R., Coleman, T. A., Dorshkind, K., McComas, W. A., Sarmiento, U. M., Rosen, C. A., and Narayanan, R., (1993) Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression, Proc Natl Acad Sci U S A, 90, 9901.
39. Offensperger, W. B., Offensperger, S., Walter, E., Teubner, K., Igloi, G., Blum, H. E., and Gerok, W., (1993) In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modilied antisense oligodeoxynucleotides, Embo J, 12, 1257.
40. Osen-Sand, A., Catsieas, M., Staple, J. K., Jones, K. A., Ayala, G., Knowles, J., Grenningloh, G., and Catsicas, S., (1993) Inhibition of axonal growth by SNAP-25 antisense oligonucleotides in vitro and in vivo [see comments], Nature, 364, 445.
41. Bennett, M. R., Anglin, S., McEwan, J. R., Jagoe, R., Newby, A. C., and Evan, G. I., (1994) Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides, J Clin Invest, 93, 820.
42. Gillardon, F., Beck, H., Uhlmann, E., Herdegen, T., Sandkuhler, J., Peyman, A., and Zimmermann, M., (1994) Inhibition of c-Fos protein expression in rat spinal cord by antisense oligodeoxynucleotide superfusion, Eur J Neurosci, 6, 880.
43. Skorski, T., Nieborowska-Skorska, M., Nicolaides, N. C., Szczylik, C., Iversen, P.,Iozzo, R. V., Zon, G., and Calabretta, B., (1994) Suppression of Philadelphial leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide, Proc Natl Acad Sci U S A, 91, 4504.
44. Stepkowski, S. M., Tu, Y., Condon, T. P., and Bennett, C. F., (1994) Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities [published erratum appears in J Immunol 1995 Feb 1; 154(3): 1521], J Immumol, 153, 5336.
45. Hijiya, N., Zhang, J., Ratajczak, M. Z., Kant, J. A., DeRiel, K., Herlyn, M., Zon, G., and Gewirtz, A. M., (1994) Biologie and therapeutic significance of MYB expression in human melanoma, Proc Natl Acad Sci U S A, 91, 4499.
46. Leonetti, C., I. D. A., Lozupone, F., Valentini, A., Geiser, T., Zon, G., Calabretta, B., Citro, G. C., and Zupi, G., (1996) Antitumor effect of c-myc antisense phosphorothioate oligodcoxynucleotides on human melanoma cells in vitro and and in mice [see comments]. J Natl Cancer Inst, 88, 419.
47. Monia, B. P., Sasmor, H., Johnston, J. F., Freier, S. M., Lesnik, E. A., Muller, M., Geiger, T., Altmann, K. H., Moser, H., and Fabbro, D., (1996) Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo, Proc Natl Acad Sci U S A, 93, 15481.
48. Yazaki, T., Ahmad, S., Chahlavi, A., Zylber-Katz, E., Dean, N. M., Rabkin, S. D., Martuza, R. L., and Glazer, R. I., (1996) Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide, Mol Pharmacol, 50, 236.
49. Iversen, P. L., Copple, B. L., and Tewary, H. K., (1995) Pharmacology and toxicology of phosphorothioale oligonucleotides in the mouse, rat, monkey and man, Toxicol Lett. 82, 425.
50. Srinivasan, S. K., and Iversen, P., (1995) Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides, J Clin Lab Anal, 9, 129.
51. Galbraith, W. M., Hobson, W. C., Gielas, P. C., Schechter, P. J., and Agrawal, S., (1994) Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey, Antisense Res Dev, 4, 201.
52. Henry, S. P., Novotny, W., Leeds,J., Auletta, C., and Kornbrust, D. J., (1997) Inhibition of coagulation by a phosphorothioate oligonucleotide, Antisense Nucleic Acid Drug Dev, 7, 503.
53. Monteith, D. K., Henry, S. P., Howard, R. B., Flournoy, S., Levin, A. A., Bennett, C. F., and Crooke, S. T., (1997) Immune stimulation - A class effect of phosphorothioate oligodeoxynucleotides in rodents, Anticancer Drug Des, 12, 421.
54. Jones, D. P., and Chesney, R. W., (1995) Renal toxicity of cancer chemotherapeutic agents in children: Ifosfamide and cisplatin, Curr Opin Pediatr, 7, 208.
55. King, P. D., and Perry, M. C., (1995) Hepatoloxicity of chemotherapeutic and oncologic agents, Gastroenterol Clin North Am, 24, 969.
56. Kimmick, G. G., Fleming, R., Muss, H. B., and Balducci, I., (1997) Cancer chemotherapy in older adults. A tolerability perspective, Drugs Aging, 10, 34.
57. Mojeik, C. F., Gourley, M. F., Klinman, D. M., Krieg, A. M., Gmelig-Meyling, F., and Steinberg, A. D., (1993) Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner, Clin Immunol Immunopathol, 67, 130.
58. Krieg, A. M., Matson, S., Cheng, K., Fisher, E., Koretzky, G. A., and Koland, J. G., (1997) Identification of an oligodeoxynucleotide sequence motif that specifically inhibits phosphorylation by protein tyrosine kinases, Antisense Nucleic Acid Drug Dev, 7, 115.
59. Zhou, L., Morocho, A. M., Chen, B. C., and Cohen, J. S., (1994) Synthesis of phosphorothioatemethylphosphonate oligonucleotide co-polymers, Nucleic Acids Res, 22, 453.
60. Nielsen, P. E., (1995) DNA analogues with nonphosphodiester backbones, Annu Rev Biophys Biomol Struct, 24, 167.
61. De Mesmaeker, A., Altmann, K. H., Waldner, A., and Wendeborn, S., (1995) Backbone modifications in oligonucleotides and peptide nucleic acid systems, Curr Opin Struct Biol, 5, 343.
62. Heidenreich, O., Gryaznov, S., and Nerenberg, M., (1997) RNase H-independent antisense activity of oligonucleotide N3 '→ P5' phosphoramidates, Nucleic Acids Res, 25, 776.
63. Perbost, M., Lucas, M., Chavis, C., Pompon, A., Baumgartner, H., Rayner, B., Griengl, H., and Imbach, J. L., (1989) Sugar modified oligonucleotides. I. Carbo-oligodeoxynucleotides as potential antisense agents, Biochem Biophys Res Commun, 165, 742.
64. Morvan, F., Porumb, H., Degols, G., Lefebvre, I., Pompon, A., Sproat, B. S., Rayner, B., Malvy, C., Lebleu, B., and Imbach, J. L., (1993) Comparative evaluation of seven oligonucleotide analogues as potential antisense agents, J Med Chem, 36, 280.
65. Kawasaki, A. M., Casper, M. D., Freier, S. M., Lesnik, E. A., Zounes, M. C., Cummins, L. L., Gonzalez, C., and Cook, P. D., (1993) Uniformly modified 2′-deoxy-2′-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets, J Med Chem, 36, 831.
66. McKay, R. A., Cummins, L. L., Graham, M. J., Lesnik, E. A., Owens, S. R., Winniman, M., and Dean, N. M., (1996) Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2′-O-propyl modifications, Nucleic Acids Res, 24, 411.
67. Griffey, R. H., Monia, B. P., Cummins, L. L., Freier, S., Greig, M. J., Guinosso, C. J., Lesnik, E., Manalili, S. M., Mohan, V., Owens, S., Ross, B. R., Sasmor, H., Wancewicz, E., Weiler, K., Wheeler, P. D., and Cook, P. D., (1996) 2′-O-aminopropyl ribonucleotides: A zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides, J Med Chem, 39, 5100.
68. Augustyns, K., Godard, G., Hendrix, C., Van Aerschot, A., Rozenski, J., Saison-Behmoaras, T., and Herdewijn, P., (1993) Hybridization specificity, enzymatic activity and biological (Ha-ras) activity of oligonucleotides containing 2,4-dideoxy-beta-D-erythro-hexopyranosyl nueleosides, Nucleic Acids Res, 21, 4670.
69. Wagner, R. W., Matteucci, M. D., Lewis, J. G., Gutierrez, A. J., Moulds, C., and Frochler, B. C., (1993) Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines, Science, 260, 1510.
70. Ojwang, J. O., Mustain, S. D., Marshall, H. B., Rao, T. S., Chaudhary, N., Walker, D, A., Hogan, M. E., Akiyama, T., Revankar, G. R., Peyman, A., Uhlmann, E., and Rando, R. F., (1997) Modified antisense oligonucleotides directed against tumor necrosis factor receptor type I inhibit tumor necrosis factor alpha-mediated functions, Biochemistry, 36, 6033.
71. Helene, C., and Thuong, N. T., (1989) Control of gene expression by oligonucleotides covalently linked to intercalating agents, Genome, 31, 413.
72. Saison-Behmoaras, T. E., Duroux, I., Nguyen, T. T., Asseline, U., and Helene, C., (1997) Antisense properties of end-modified oligonucleotides targeted to Ha-ras oncogene, Antisense Nucleic Acid Drug Dev, 7, 361.
73. Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., and Freier, S. M., (1993) Evaluation of 2′-modified oligonueleotides containing 2′-deoxy gaps as antisense inhihitors of gene expression. J Biol Chem, 268, 14, 514.
74. Monia, B. P., Johnston, J. F., Sasmor, H., and Cummins, L. L., (1996) Nuclease resistance and antisense activity of modified oligonucleotides largeted to Ha-ras, J Biol Chem, 271, 14, 533.
75. Agrawal, S., Jiang, Z., Zhao, Q., Shaw, D., Cai, Q., Roskey, A., Channavajjala, L., Saxinger, C., and Zhang, R., (1997) Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies, Proc Natl Acad Sci U S A, 94, 2620.
76. Agrawal S and Zhang R. (1998) Pharmacokinetics and bioavailability of oligonucleotides following oral and colorectal administration in experimental anireals. In: Crooke ST, ed. Antisense Research and Application. Vol. 131. Berlin: Springer, 525-543.
77. Anderson, K. P., Fox, M. C., Brown-Driver, V., Martin, M. J., and Azad, R. F., (1996) Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA, Antimicrob Agents Chemother, 40, 2004.
78. Lieberman, D. V., and Hardin, C. C., (1997) Analytic extraction of information on the buildup and consumption of reactive intermediates from experimental quadruplex DNA assembly timecourses, Nucleic Acids Symp Ser, 184.
79. Muccioli C, Goldstein DA, Johnson DW, Perez JE, Mora-Duarte JF, Sheppard JD, Mansour SE, Chan CK, Palestine AG, Grillone LR and Chandler JW (1998) Fomivirsen safely and efficacy in the treatment of CMV retinitis: A phase 3, controlled, multicenter study comparing immediate versus delayed treatment. 5th Conference on Retroviruses and Opportunistic Infections; Feb. 1-5:224.
80. Ho, P. T., and Parkinson, D. R., (1997) Antisense oligonucleotides as therapeutics for malignant diseases, Semin Oncol, 24, 187.
81. Orr RM and Monia BP (1998) Antisense therapy for cancer. Cur Res Mol Ther 1, 102-108.
82. Neumanaitis J, Von Hoff DD, Holmlund J, Dorr A and Eckhardt SG (1998) Phase I/pharmacokinetic (PK) trial of a protein kinase C-alpha antisense oligonucleolide, ISIS 3521 (CGP 64128A), administered thrice weekly. Proc ASCO 17, 211a.
83. Sikic BI, Yuen AR, Advani R, Halsey J, Fisher GA, Holmlund J and Dorr A (1998) Antisense oligonucleotide therapy targeted to protein kinase C-alpha (ISIS 3521/CGP 64128A) by 21 day infusion: Results of the phase I trial and activity in ovarian carcinomas. Proc ASCO 17, 429a.
84. Holmlund J, Neumanaitis J, Schiller J, Dorr A and Kisner D (1998) Phase I trial of c-raf antisense oligonueleotide ISIS 5132 (CGP 69846A) by 21-day continuous intravenous infusion (CIV) in patients with advanced cancer. Proc ASCO 17, 210a.
85. O'Dwyer PJ, Stevenson JP, Gallagher M, Mitchell E, Friedland D, Rose L, Cassella A, Holmlund J, Dean N, Dorr A, Geary R and Yao K-S (1998) Phase I/pharmacokinetic/pharmacodynamic trial of raf-I antisense ODN (ISIS 5132, CGP 69846A). Proc ASCO 17, 210a.
86. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., di Stefano, F., Ross, P., Corbo, M., and Dziewanowska, Z., (1997) BCL-2 antisense therapy in patients with non-Hodgkin lymphoma, Lancet, 349, 1137.
87. Yacyshyn, B. R., Bowen-Yacyshyn, M. B., Jewell, L., Tami, J. A., Bennett, C. F., Kisner, D. L., and Shanahan, W. R., Jr., (1998) A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease, Gastroenterology, 114, 1133.
88. Bernstein, C. N., Sargent, M., Gallatin, W. M., and Wilkins, J., (1996) Beta 2-integrin/intercellular adhesion molecule (ICAM) expression in the normal human intestine, Clin Exp Immunol, 106, 160.
89. Meenan, J., Spaans, J., Grool, T. A., Pals, S. T., Tytgat, G. N., and van Deventer, S. J., (1997) Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation, Gut, 40, 241.